α-Klotho is a transmembrane glycoprotein and hormone that has emerged as one of the most compelling longevity-associated proteins in biomedical research. Named after the Greek Fate who spins the thread of life, Klotho governs phosphate homeostasis, suppresses cellular senescence, protects against fibrosis, and coordinates anti-aging signaling across the kidney, brain, heart, and vasculature. Its progressive decline with age — and with virtually every major chronic disease — positions Klotho at the intersection of aging biology and multi-organ protection research.
What Is Klotho?
Discovered in 1997 by Makoto Kuro-o and colleagues at the National Institute of Neuroscience in Japan, α-Klotho was identified through a fortuitous insertional mutation in mice that produced a syndrome strikingly similar to accelerated human aging — including atherosclerosis, osteoporosis, pulmonary emphysema, skin atrophy, and shortened lifespan. Since that landmark observation (Kuro-o et al., Nature, 1997; PMID 9363890), Klotho has become one of the most intensively studied proteins in longevity and aging biology.
Structurally, α-Klotho is a single-pass type-I transmembrane glycoprotein of approximately 130 kDa, encoded by the KL gene on chromosome 13q12. Its large extracellular domain contains two homologous β-glucuronidase-like KL1 and KL2 repeats, both of which contribute to downstream signaling functions. Proteolytic shedding by membrane proteases (including ADAM10 and ADAM17) releases the extracellular domain into the circulation as soluble Klotho (sKL), which functions as an endocrine and paracrine factor distinct from the membrane-tethered isoform.
> Research Use Only. All content on peptides.so is intended for in vitro and preclinical research use only. Klotho protein, recombinant Klotho fragments, and Klotho-derived peptides are laboratory research reagents and are not approved for human or veterinary therapeutic use.
---
Klotho Isoforms: α, β, and γ
Three Klotho family members have been characterized in mammals:
| Isoform | Co-receptor for | Primary expression sites | Key research relevance |
|---|---|---|---|
| α-Klotho | FGF23 (via FGFR1c/3c/4) | Kidney (distal tubule), choroid plexus, parathyroid | Aging, CKD, neuroprotection, calcium/phosphate homeostasis |
| β-Klotho | FGF19, FGF21 (via FGFR1c/4) | Liver, adipose tissue, pancreas | Bile acid metabolism, energy expenditure, metabolic syndrome |
| γ-Klotho | FGF19, FGF23 (weak) | Retina, skin | Ocular biology, limited characterization |
The overwhelming majority of aging and longevity research focuses on α-Klotho. Unless otherwise specified, "Klotho" in the research literature refers to α-Klotho, and that convention is followed throughout this profile.
---
Molecular Structure and Klotho-Derived Peptide Fragments
The extracellular domain of α-Klotho comprises approximately 952 amino acids organized into two β-glucuronidase homology domains:
- •KL1 domain (residues ~80–506): Mediates TGF-β, Wnt, and IGF-1 signaling modulation. KL1-derived peptide fragments recapitulate many cytoprotective effects of full-length soluble Klotho and have emerged as pharmacologically tractable candidates for in vitro research.
- •KL2 domain (residues ~515–953): Critical for FGFR1 binding and the formation of the ternary FGF23/FGFR/Klotho complex. Required for canonical renal phosphate-wasting signaling.
The most pharmacologically advanced Klotho-derived peptide to emerge in preclinical research is KP1 — a 30-amino-acid fragment derived from the KL1 domain. KP1 has been shown to inhibit TGF-β/TβR2 engagement, suppress renal fibroblast activation, ameliorate kidney fibrosis, and restore endogenous Klotho expression at the posttranscriptional level (Nature Communications, 2022; DOI 10.1038/s41467-022-28096-z). Subsequent work demonstrated that KP1 also inhibits cellular senescence markers (p21, p16, γ-H2AX) in tubular epithelial cells and showed protective activity in models of SARS-CoV-2-associated acute kidney injury (PMC10750200; PMC10795167).
High-affinity peptide probes targeting α-Klotho have also been developed through in-solution size-exclusion affinity selection-mass spectrometry, achieving approximately 2,300-fold improvement in binding affinity over initial hits — enabling new biosensor and imaging research applications (JACS Au, 2024; PMC11040699).
---
Mechanisms of Action
1. FGF23 Co-Receptor and Mineral Homeostasis
α-Klotho''s most characterized function is as an obligate co-receptor for fibroblast growth factor 23 (FGF23) in the renal distal tubule. Membrane α-Klotho binds to FGFR1c, FGFR3c, and FGFR4, dramatically increasing their affinity for FGF23 — which, in isolation, binds FGFRs only weakly. The assembled 2×FGF23/2×FGFR/Klotho ternary complex drives downstream ERK1/2 and SGK1 signaling to suppress proximal tubular sodium-phosphate cotransporter (NaPi-IIa/IIc) expression, reducing phosphate reabsorption and increasing urinary phosphate excretion (Nat Rev Cardiol, 2023; PMID 37443358).
Klotho also suppresses 1α-hydroxylase activity, reducing renal conversion of 25-hydroxyvitamin D to calcitriol, and modulates parathyroid hormone secretion. The net effect is a tightly coordinated reduction in serum phosphate — an axis critically disrupted in chronic kidney disease (CKD).
2. TGF-β Pathway Antagonism
Soluble Klotho binds directly to TGF-β1 and prevents its interaction with TGF-β receptor type II (TβR2), attenuating downstream SMAD2/3 phosphorylation. This mechanism underlies Klotho''s anti-fibrotic activity in kidney, cardiac, and pulmonary models and positions soluble Klotho (and KP1) as potential anti-fibrotic research tools independent of FGF23 signaling.
3. Wnt/β-Catenin Inhibition
Soluble Klotho functions as a pan-Wnt ligand antagonist by binding Wnt ligands directly and preventing receptor engagement. Since aberrant Wnt/β-catenin activation drives senescence programs, fibrosis, and some cancer phenotypes, Klotho''s Wnt antagonism has attracted interest in aging, CKD, and oncology research contexts.
4. Oxidative Stress Modulation
α-Klotho upregulates antioxidant defenses by suppressing phosphatidylinositol 3-kinase/AKT/FOXO signaling, which normally inhibits FOXO transcription factors responsible for expressing manganese superoxide dismutase (MnSOD) and catalase. Klotho-deficient mice show elevated oxidative stress markers, and Klotho supplementation reduces reactive oxygen species in multiple preclinical models.
5. IGF-1 Signaling Suppression
By inhibiting the PI3K/AKT axis downstream of IGF-1R, Klotho recapitulates aspects of caloric restriction-like signaling associated with extended lifespan in multiple model organisms. This mechanism may contribute to Klotho''s longevity effects independent of its FGF23 co-receptor role.
6. NMDA Receptor Modulation
In neural tissue, soluble Klotho enhances GluN2B-containing NMDA receptor function through interactions involving myelin-associated glycoprotein (MAG) modulation. A 2025 meta-analysis of 6,645 subjects confirmed a positive correlation between circulating Klotho levels and cognitive performance, consistent with preclinical evidence of Klotho''s role in synaptic plasticity and neurogenesis.
---
Research Applications
Kidney and Renal Fibrosis Research
Klotho is most highly expressed in the kidney — specifically in distal convoluted tubule epithelium — and its progressive loss is one of the earliest and most consistent molecular events in CKD progression. Circulating sKL declines before GFR drops measurably, making it a candidate early biomarker for kidney dysfunction. In CKD models, exogenous sKL administration has been shown to:
- •Suppress FGF23-induced cardiac hypertrophy
- •Attenuate renal tubular injury and inflammation
- •Reduce phosphate retention
- •Preserve tubular cell viability against ischemia-reperfusion injury
KP1 specifically has validated the TGF-β/anti-fibrotic pathway in multiple kidney fibrosis models, with effects on both prevention and reversal of established fibrosis in rodent experiments (American Journal of Kidney Diseases, 202200620-5/fulltext)).
For researchers studying CKD models, recombinant murine or human α-Klotho protein (amino acids 1–952 or truncated KL1 domain) is the primary research tool. Purity specifications of ≥90% (SDS-PAGE) and endotoxin <1 EU/μg are standard for in vitro cell culture applications.
Cardiovascular Research
Klotho deficiency is strongly associated with vascular calcification, endothelial dysfunction, and cardiac hypertrophy in both mouse models and human epidemiological data. The cardiovascular axis operates through two primary mechanisms:
1. FGF23 cardiotoxicity: In CKD, FGF23 rises compensatorily as renal Klotho falls. Without sufficient Klotho as a co-receptor buffer, FGF23 signals directly through FGFR4 in cardiomyocytes, activating PLCγ/calcineurin/NFAT to drive pathological cardiac hypertrophy.
2. Direct endothelial protection: Soluble Klotho promotes endothelial nitric oxide synthase (eNOS) activity and suppresses TNF-α-induced endothelial inflammation through NF-κB inhibition.
A comprehensive review from the ERA CKD-MBD working group (2024) underscores Klotho''s role as a vascular protector and potential therapeutic target extending well beyond renal disease (Clinical Kidney Journal, PMC10783249).
Neuroprotection and Cognitive Research
The choroid plexus — the site of cerebrospinal fluid (CSF) production — expresses α-Klotho at levels second only to the kidney, situating it as a major regulator of the central nervous system microenvironment. Preclinical and translational research highlights include:
- •Aged rodent cognitive enhancement: Systemic delivery of recombinant Klotho protein improved spatial memory and learning in aged mice even at sub-physiological doses, suggesting receptor-mediated mechanisms in neural tissue.
- •Non-human primate evidence: A 2023 Nature Aging publication demonstrated significant cognitive enhancement in aged rhesus macaques following systemic Klotho administration, representing a key translational step.
- •Hippocampal neurogenesis: Brain-targeted Klotho delivery promoted generation of new neurons in the hippocampal dentate gyrus and increased immune surveillance activity in aged animal models.
- •Alzheimer''s disease associations: Lower circulating Klotho levels correlate with increased amyloid burden and hippocampal atrophy in observational studies. Klotho''s Wnt inhibition may reduce amyloid precursor protein processing through β-secretase pathways.
The anti-inflammatory role of Klotho in the CNS is attracting increasing attention, with evidence that sKL downregulates microglial NF-κB activation and reduces neuroinflammatory cytokine production (PMC, 2024; Anti-Inflammatory Role, PMC11394293).
Aging and Longevity Research
The foundational longevity finding remains Kurosu et al. (2005), who demonstrated that transgenic mice overexpressing Klotho lived 20–30% longer than wild-type controls and showed resistance to insulin/IGF-1 signaling-associated pathologies (Science, 2005; PMID 16123266). Conversely, Klotho-null mice die prematurely at approximately 8–12 weeks with the full complement of age-related phenotypes.
2025 research has extended these findings: increasing Klotho protein levels in aged mice extended lifespan by 15–20%, improved physical performance, preserved muscle fiber size, and reduced fibrosis. This post-hoc elevation paradigm is particularly relevant for translational research because it suggests intervention in already-aged subjects may show measurable effects.
Klotho levels in humans decline approximately 30–40% between ages 25 and 80, paralleling the trajectory of many other longevity-associated proteins. Multiple polymorphisms in the KL gene have been associated with longevity in centenarian cohorts, particularly the KL-VS allele (F352V and C370S substitutions), which has been linked to both cognitive preservation and extended lifespan in some populations.
Bone Biology Research
Through its role in the FGF23/Klotho axis, α-Klotho regulates phosphate, calcium, and vitamin D metabolism — all critical inputs to skeletal mineralization. In CKD models, declining Klotho disrupts FGF23 signaling, leading to secondary hyperparathyroidism, renal osteodystrophy, and elevated vascular calcification risk. Research into Klotho as a bone-protective factor is active, particularly regarding its interaction with the RANK/RANKL/OPG axis governing osteoclast differentiation.
Cancer Biology Research
Klotho has emerged as a putative tumor suppressor in multiple cancer models. Via inhibition of the Wnt/β-catenin and IGF-1R/PI3K/AKT pathways — both commonly hyperactivated in malignancy — Klotho overexpression suppresses proliferation, migration, and invasion in breast, lung, pancreatic, and colorectal cancer cell lines. Conversely, epigenetic silencing of the KL promoter through methylation has been observed across multiple human tumor types, suggesting Klotho loss may be a contributing event in cancer progression. This area is entirely preclinical and represents a novel research angle distinct from Klotho''s aging biology.
---
Klotho as a Research Biomarker
Because Klotho expression declines with age and with nearly every major chronic disease studied (CKD, heart failure, diabetes, Alzheimer''s disease, cancer), circulating sKL has been proposed as a composite biomarker of biological age and systemic health. Validated enzyme-linked immunosorbent assay (ELISA) kits targeting the KL1 domain of human sKL are commercially available for serum and CSF research applications.
Approximate reference ranges in healthy adults:
- •Serum sKL: ~500–1,200 pg/mL (declines with age)
- •CSF sKL: ~600–1,500 pg/mL
- •Urinary sKL: under active investigation as a kidney-specific biomarker
Standardization across ELISA platforms remains an active area of research, with inter-assay variability a known limitation for multi-site studies.
---
Research Tools and Reagent Formats
Klotho is available to qualified research laboratories in several formats:
| Format | Description | Typical applications |
|---|---|---|
| Recombinant human α-Klotho (full ectodomain) | aa 34–981, HEK293 or CHO expression, typically His-tagged | Binding assays, in vitro signaling, cell culture |
| Recombinant murine α-Klotho | Species-matched for rodent in vivo experiments | Rodent model supplementation studies |
| KL1 domain fragment | aa 34–506 only | TGF-β inhibition, Wnt inhibition assays |
| KP1 synthetic peptide | 30-mer derived from KL1, >95% purity | Renal fibrosis models, anti-senescence studies |
| Anti-Klotho antibodies | Monoclonal and polyclonal, multiple epitopes | ELISA, IHC, WB, flow cytometry |
| Klotho ELISA kits | Sandwich ELISA for human/murine serum, urine, CSF | Biomarker quantification |
Storage considerations: Recombinant Klotho protein should be stored at −80°C in carrier protein (typically 0.1% BSA) to prevent surface adsorption losses. Lyophilized formats offer longer shelf stability. Repeated freeze-thaw cycles substantially reduce activity; aliquoting upon receipt is recommended.
---
Klotho Research in the Context of Other Longevity Compounds
Researchers studying the biology of aging will find Klotho functionally intersecting with several other compounds profiled on this platform:
- •Epitalon (AEDG Tetrapeptide): Like Klotho, Epitalon operates via pineal/neuroendocrine pathways and telomere biology — both represent distinct anti-aging research paradigms.
- •SS-31 (Elamipretide) and MOTS-c: Mitochondria-targeted peptides that complement Klotho''s oxidative stress modulation research.
- •IGF-1: Klotho and IGF-1 signaling intersect at the PI3K/AKT node; Klotho''s IGF-1R suppression is mechanistically related to longevity phenotypes in model organisms.
- •NAD+: Both NAD+ precursors and Klotho converge on mitochondrial function and oxidative stress research.
- •Humanin: Another endogenous longevity-associated peptide with cytoprotective and metabolic research relevance.
- •FOXO4-DRI (Proxofim): The intersection of Klotho''s cellular senescence suppression (via FOXO/p21/p16 pathways) with senolytics represents an emerging research area in tissue aging biology.
---
Key Research Gaps and Active Directions (2025–2026)
Several questions remain at the frontier of Klotho research:
1. Delivery optimization: Full-length recombinant Klotho (130 kDa) has limited tissue penetration and a short half-life in vivo. KL1-derived peptide fragments like KP1 (30 aa) offer pharmacokinetic advantages. Gene therapy approaches using adeno-associated virus vectors delivering KL have shown 20% lifespan extension in preclinical models.
2. Blood-brain barrier crossing: Mechanisms by which systemic sKL accesses CNS compartments remain debated. Some evidence supports receptor-mediated transcytosis; direct CSF delivery is being explored for neurodegenerative disease models.
3. β-Klotho therapeutic potential: FGF21 signaling through β-Klotho/FGFR1c is an active area for metabolic syndrome and MASH (metabolic-associated steatohepatitis) research, with several bispecific FGF21 agonist programs in clinical development.
4. Klotho-VS allele biology: The functional consequences of the common KL-VS polymorphism for cognitive aging and its interaction with APOE status are under active investigation.
5. Synergy with senolytics: The intersection of Klotho''s cellular senescence suppression with senolytic peptides represents an emerging area in the biology of tissue aging.
---
Summary
α-Klotho stands as one of the most pleiotropic longevity-associated proteins identified in biomedical research. From its discovery as a murine aging-suppressor gene to its current status as a near-translational cognitive enhancer and renal protector, Klotho''s research profile spans mineral metabolism, cardiovascular biology, neuroprotection, anti-fibrosis, and cancer suppression. The emergence of pharmacologically tractable fragments — particularly KP1 and KL1 domain peptides — has opened a new chapter in Klotho research by enabling cell-permeant and injectable peptide tools distinct from the large full-length protein. As circulating Klotho declines predictably with aging and chronic disease, its role as both a research target and a biological age biomarker continues to expand in scope.
Further reading:
- •Kuro-o et al., Nature 1997 (PMID 9363890) — Discovery paper
- •Kurosu et al., Science 2005 (PMID 16123266) — Klotho overexpression extends lifespan
- •KP1 peptide anti-fibrotic study, Nature Communications 2022
- •ERA CKD-MBD working group review, Clinical Kidney Journal 2024 (PMC10783249)
- •FGF23 and Klotho at the intersection of CKD and CVD, Nature Reviews Cardiology 2023 (PMID 37443358)